August 12, 2021
A new cancer immunotherapy pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue. The approach could make chimeric antigen receptor (CAR) T-cell therapy safer and effective at treating solid tumors.
November 30, 2018
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.
April 29, 2015
Researchers at the University of California, San Diego School of Medicine report that blocking or removing immune-suppressing cells allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of…
April 26, 2021
A multi-institutional team of researchers, led by UC San Diego School of Medicine and Moores Cancer Center, has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy.
September 16, 2016
In a Perspective piece published this week in PNAS, cancer researchers from across the country, including faculty at University of California San Diego School of Medicine and Moores Cancer Center, write that a greater emphasis on immune-based prevention should be central to new efforts like the federal Cancer Moonshot program,…
November 24, 2021
The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
February 23, 2016
…to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells – one of the immune system’s primary weapons – to treat three different types of blood cancer that often defy existing therapies.
March 7, 2017
Honjo received the 2016 Kyoto Prize—Japan’s highest private award for global achievement—in the area of “Basic Sciences” for his contributions to medical science. His work has been described as initiating a historic turning point—a “penicillin moment”—in the fight against cancer.
February 5, 2019
To make it easier for patients to receive world-class cancer care, UC San Diego Health has added a new multidisciplinary cancer clinic in Hillcrest and expanded its infusion center for both oncology patients and others in need of infusion services.
March 26, 2014
Napoleone Ferrara, MD, distinguished professor of pathology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today among eight recipients of the Canada Gairdner Awards at a ceremony in Toronto.
